Is RMD a Good Stock to Buy? The Bull and Bear Case (2026)

Last updated November 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for ResMed (RMD) rests on Resupply, not new device placements, carries the growth: Masks and other consumables grew 10% in the Americas and 12% internationally on a constant currency basis in the June 2026 quarter, faster than device revenue in both regions. The bear case rests on philips is the single largest competitive variable. Analysts covering it publish targets from $210.00 to $320.00 against a $235.63 share price on November 20, 2026, so even the professionals disagree by 42% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

RMD key stats

At $235.63 on November 20, 2026, ResMed (RMD) has a market cap of $33.1B, a P/E of 21.5 on trailing earnings (17.8 on forward earnings) and a dividend yield of 1.12%. It next reports earnings around January 28, 2027 (estimated).

Market cap
$33.1B
P/E (trailing)
21.5
P/E (forward)
17.8
EPS (trailing 12 months)
$10.98
Price to book
5.6
Dividend yield
1.12%
Beta
0.76
Next earnings
around January 28, 2027 (estimated)

Market cap, P/E and yield are measured at the $235.63 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with ResMed (RMD)?

The last two weeks for ResMed, as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • RMD closed at $235.63 on November 20, 2026, down 1.6% over the past five trading days (from $239.53).
  • ResMed next reports quarterly results around January 28, 2027 (estimated).
  • On November 19, 2026, ResMed filed an 8-K with the SEC reporting a change in its directors or officers and the results of a shareholder vote (Item 5.02, Item 5.07). Read the 8-K on sec.gov

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

ResMed sells the equipment and software used to treat sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions outside the hospital. The hardware side splits into flow generators (the AirSense and AirCurve device families, plus the Astral and Stellar life support ventilators) and the masks, cushions, tubing and filters patients replace on a rolling schedule. In fiscal 2026, the year ended June 30, 2026, Americas devices produced ~$1.77 billion and Americas masks and other ~$1.51 billion, while the rest of the world contributed ~$1.12 billion in devices and ~$572 million in masks. A third line, Residential Care Software, brought in ~$676 million from Brightree, MEDIFOX DAN and MatrixCare, the back office systems that home medical equipment dealers, out of hospital care providers and skilled nursing operators use for billing, resupply and scheduling. Roughly 11,370 employees support ~35 million cloud connected devices and ~37 million patients registered in AirView, the remote monitoring platform. Manufacturing is concentrated in Singapore, Sydney and Tijuana. The company is incorporated in Delaware, reports in US dollars, lists on the NYSE, and also trades in Australia as CHESS Depositary Interests. The economics look less like a device maker than the sector label suggests. Gross margin reached 61.1% on a GAAP basis in fiscal 2026 and 62.4% non-GAAP, up 240 basis points year on year, helped by manufacturing efficiency and a mix shift toward masks. Operating margin was 33.4% GAAP, net income $1.52 billion, and diluted EPS $10.43 GAAP against $11.17 non-GAAP. Free cash flow came in at ~$1.65 billion on ~$1.81 billion of operating cash flow, which funded $700 million of buybacks and $350 million of dividends. The balance sheet carries ~$1.47 billion of cash against ~$659 million of debt, so at fiscal year end the enterprise value sat slightly below the equity market capitalisation. What investors are actually paying for is the annuity: a patient set up on a device replaces cushions and masks for years, and Brightree sits inside the resupply workflow that triggers those reorders. What they are discounting is the pair of open questions on the tape: the Astral field safety action and GLP-1 substitution. Management guided fiscal 2027 to $5.75 billion to $5.85 billion of revenue and $12.00 to $12.25 of non-GAAP EPS, both after absorbing the Astral hit and the MatrixCare sale. The first quarter of that year, reported in late October, came in at ~$1.41 billion of revenue, up ~5.9% from a year earlier and slightly above the ~$1.39 billion consensus, with GAAP net income of ~$418 million and non-GAAP EPS of $2.91 against ~$2.67 expected. Trailing twelve month revenue is now ~$5.73 billion and net income ~$1.59 billion. The shares closed at $238.24 on November 20, 2026, giving a market capitalisation of ~$33.5 billion. That is ~2.7% lower for the year to date, ~2.3% lower than a year earlier and ~5.8% lower over the past month, roughly flat over three months, and well above the summer low near the $180.27 bottom of its 52 week range. The next report, for the December quarter, is estimated for around January 28, 2027, with consensus near $2.99 of EPS on ~$1.46 billion of revenue.

The bull case: what would have to be true for $320.00

The most optimistic published target on RMD is $320.00, +35.8% from the $235.63 share price on November 20, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Resupply, not new device placements, carries the growth

Masks and other consumables grew 10% in the Americas and 12% internationally on a constant currency basis in the June 2026 quarter, faster than device revenue in both regions. That matters because a mask sale is repeatable and higher margin, while a flow generator is a one time placement every five years or so. The installed base of ~35 million connected devices is the denominator, and Brightree's resupply automation is what converts it into orders. ResMed reports ~37 million patients in AirView, a figure that only moves in one direction as long as new setups exceed attrition. Gross margin expansion of 240 basis points non-GAAP in fiscal 2026 came substantially from this mix shift.

2. The Astral recall is a sized, dated hole rather than an open ended one

ResMed issued a global medical device correction for Astral 100 and Astral 150 ventilators built before October 2024, covering 168,069 units, after finding that an internal supercapacitor can leak electrolyte, damage the circuit board and push the device into a fail safe state that stops ventilation. The FDA classified it Class 1 (recall number Z-2735-2026, initiated June 25, 2026, posted July 28), with five serious injuries and no deaths reported as of June 23, 2026. Management took a $42 million provision in the fourth quarter, suspended new Astral sales while prioritising the most severe patients, and guided to roughly $75 million of lost fiscal 2027 revenue. Against $5.65 billion of fiscal 2026 sales, that is about 1.3 points of growth.

3. Software is being pruned, not scaled

Residential Care Software grew only 4% in constant currency in fiscal 2026, the slowest of the three revenue lines. In July 2026 ResMed agreed to sell MatrixCare, the skilled nursing and out of hospital care platform, to Frazier Healthcare Partners for $490 million, with the deal expected to close in the first quarter of fiscal 2027 and $457 million already sitting in assets held for sale at June 30, 2026. The retained software assets, Brightree and MEDIFOX DAN, sit much closer to the device and resupply flow. The divestiture shrinks reported revenue and removes the slowest growing piece, so fiscal 2027 comparisons need to be read on a core, constant currency basis.

4. ResMed's own GLP-1 data cuts against the short thesis

The bear case since Eli Lilly's Zepbound was cleared for obstructive sleep apnea has been that weight loss drugs shrink the addressable patient pool. ResMed's response is a study of 2.5 million patients showing that people prescribed a GLP-1 were 1,070 basis points more likely to start PAP therapy than a matched non-GLP-1 cohort, with better resupply rates at one and three years after setup. The mechanism is plausible: a patient engaged enough with their weight to fill a GLP-1 prescription is a patient more likely to seek a sleep diagnosis. Short interest stood at ~10.9% of shares outstanding in August 2026, which is unusually high for a large cap medtech and shows the market has not accepted the argument.

5. The first fiscal 2027 quarter cleared a low bar

ResMed reported its first quarter of fiscal 2027 (the September 2026 quarter) in late October. Consensus had sat at ~$2.67 of EPS on ~$1.39 billion of revenue, pencilling in only ~4.6% EPS growth against $2.55 a year earlier, a low bar set by the Astral sales suspension and the MatrixCare divestiture. The company delivered ~$1.41 billion of revenue, up ~5.9%, and $2.91 of non-GAAP EPS, a $0.24 beat and its fifth straight, after beats of $0.05 to $0.09 in the four quarters before. GAAP net income was ~$418 million, the highest of the last four quarters. The stock did not rerate on it: it closed at $238.24 on November 20, 2026, ~5.8% lower over the month. The 17 analysts tracked carry a mean target near $264, about 11% above that close, and expect ~$2.99 of EPS on ~$1.46 billion of revenue for the December quarter, due around January 28, 2027.

The bear case: what would have to be true for $210.00

The most pessimistic published target is $210.00, -10.9% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks ResMed is worth if the risks below bite instead of the drivers above.

Philips is the single largest competitive variable. Its Respironics business exited most of the US new device market after the 2021 foam recall and the subsequent consent decree, handing ResMed several points of share it did not have to compete for. Any credible return of Philips capacity to the US sleep market would meet a ResMed that has been pricing and allocating capital against a diminished rival for five years, and mask share, where switching costs are lowest, would be the first place to show it. The GLP-1 question is genuinely open. ResMed's 2.5 million patient study is observational and self published, and it measures behaviour in the early years of drug adoption rather than the steady state after sustained weight loss; a cohort that loses enough weight to fall below the diagnostic threshold would leave the resupply base entirely. Quality systems are the second live risk. A Class 1 designation on 168,069 Astral units invites FDA scrutiny that can extend past the specific defect into inspection findings, warning letters or a consent decree, and Philips is the cautionary case for how far that can go. Reimbursement adds pressure from the other side: most US revenue passes through home medical equipment suppliers paid by Medicare and commercial plans, so competitive bidding rounds and prior authorisation tightening compress the distributor before they reach ResMed. Manufacturing is concentrated in Singapore, Sydney and Tijuana, which leaves the gross margin exposed to tariffs and freight. Roughly a third of revenue is non-US, so a stronger dollar reduces reported growth. Finally, short interest near 10.9% in August and a 52 week range of $180.27 to $277.67, with the stock ~2.3% lower over a year even as trailing GAAP earnings grew to ~$1.59 billion and quarterly earnings rose ~23% year on year, mean sentiment, not fundamentals, has been setting the price. Revenue growth of ~5.9% in the September quarter, down from 9% in June, is the number the GLP-1 bears will point to until the Astral and MatrixCare effects lap.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding RMD already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on RMD

17 analysts cover RMD, with an average target of $264.33 (+12.2% against $235.63) and a split of 9 buy, 10 hold, 1 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the RMD forecast and price target page.

How is RMD valued?

Market cap, P/E and dividend yield at today's price are in the RMD key stats above. The business figures below come from ResMed's reported results as of November 2026 and change when it next reports.

  • Revenue (trailing twelve months and fiscal 2026): ~$5.73 billion for the twelve months to September 30, 2026. Fiscal 2026, the twelve months ended June 30, 2026, brought ~$5.65 billion, up ~10% reported and ~8% in constant currency from ~$5.15 billion in fiscal 2025, ~$4.69 billion in fiscal 2024 and ~$4.22 billion in fiscal 2023. The September 2026 quarter, the first of fiscal 2027, produced ~$1.41 billion, up ~5.9% year on year and slightly above the ~$1.39 billion consensus, after the Astral sales suspension and the MatrixCare divestiture.
  • Earnings and margins: Trailing twelve month GAAP net income of ~$1.59 billion and trailing GAAP EPS of ~$10.98, on a ~61.8% gross margin, ~34.0% operating margin and ~27.8% net margin. September 2026 quarter GAAP net income was ~$418 million, up ~23% year on year, and non-GAAP EPS was $2.91 against ~$2.67 expected. For fiscal 2026, GAAP diluted EPS was $10.43 and non-GAAP $11.17, up 17%, with GAAP gross margin of 61.1% and non-GAAP 62.4%; the fourth quarter carried a $42 million Astral provision.
  • Revenue mix (the line a screener misses): Fiscal 2026 devices totalled ~$2.89 billion (~$1.77 billion Americas, ~$1.12 billion rest of world), masks and other consumables ~$2.09 billion (~$1.51 billion Americas, ~$572 million rest of world), and Residential Care Software ~$676 million. Sleep and Breathing Health was ~$4.98 billion of the total. Masks grew 10% in the Americas and 12% internationally in the fourth quarter on a constant currency basis, against ~4% constant currency growth for software across the year.
  • Cash flow and balance sheet: Trailing operating cash flow of ~$1.77 billion and free cash flow of ~$1.30 billion, per Yahoo Finance, against ~$1.81 billion and ~$1.65 billion for fiscal 2026. Cash of ~$1.01 billion against ~$611 million of total debt at September 30, 2026, a net cash position and a debt to equity ratio near 0.10. Cash was ~$1.47 billion at June 30, 2026, when ~$457 million of assets were held for sale for the pending MatrixCare disposal.
  • Capital returns: ResMed returned more than $1 billion to shareholders in fiscal 2026, roughly 70% more than the prior year: ~$700 million of buybacks and ~$350 million of dividends. The quarterly dividend was raised 10% to $0.66 per share in August 2026, an annualised $2.64 and a yield near 1.1% at the November 20 close of $238.24, on a payout ratio around 22% of trailing GAAP earnings. Management guided to more than $1.85 billion of combined buybacks and dividends in fiscal 2027.
  • Market pricing: Shares closed at $238.24 on November 20, 2026, inside a 52 week range of $180.27 to $277.67: down ~5.8% over one month, up ~0.7% over three, down ~2.7% year to date and ~2.3% over twelve months. Market capitalisation is ~$33.5 billion. That works out to ~21.7x trailing GAAP EPS of ~$10.98, ~18.0x forward EPS of ~$13.23, ~5.9x sales and ~15.5x EV/EBITDA. The 17 analysts tracked rate it a buy on average, with a mean target near $264.
  • Next report (fiscal Q2 2027): Estimated for around January 28, 2027. Consensus calls for EPS of ~$2.99 on revenue of ~$1.46 billion, about 6.4% EPS growth. For the full fiscal year to June 2027, analysts average ~$12.14 of EPS on ~$5.83 billion of revenue, inside management's guidance; fiscal 2028 estimates sit near $13.23 and ~$6.21 billion. The last five quarters all beat EPS consensus: $2.55 vs $2.50, $2.81 vs $2.72, $2.86 vs $2.80, $2.95 vs $2.89 and $2.91 vs $2.67.

As of November 2026: At ~$238 the stock trades near 21.7x trailing GAAP earnings and ~18x forward estimates, below the ~30x it commanded before the GLP-1 debate began. Fiscal 2027 guidance of $5.75 billion to $5.85 billion of revenue and $12.00 to $12.25 of non-GAAP EPS absorbs the ~$75 million Astral headwind and the MatrixCare sale, and the first quarter's $2.91 of non-GAAP EPS puts the year on pace for the upper half of that range if it repeats, while revenue growth of ~5.9% sits inside the 5% to 7% core guide. Mature medtech multiple, double digit EPS growth target: that is the valuation argument in one line.

How do you decide if RMD is a buy?

Whether RMD is a buy is easier to judge through four narrower questions:

  • Thesis: do you believe the bull case above, and is it still true today?
  • Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
  • Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
  • Overlap: check whether you already hold RMD indirectly through an index or sector ETF before adding more.

What would change your mind on RMD

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

  • Bull case breaks if: Resupply, not new device placements, carries the growth stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
  • Bear case breaks if: philips is the single largest competitive variable fails to materialise over several reporting periods while the drivers keep compounding.
  • Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the RMD stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about RMD against your real portfolio and see your actual exposure before deciding.

Your questions about ResMed

Ask Walnut's AI anything about RMD and see how it fits what you own.

FAQ

Is RMD a good stock to buy right now?

+

That depends on which case you find more convincing, and both are on this page. The bull case rests on Resupply, not new device placements, carries the growth, with revenue (trailing twelve months and fiscal 2026) at ~$5.73 billion for the twelve months to September 30, 2026. Fiscal 2026, the twelve months ended June 30, 2026, brought ~$5.65 billion, up ~10% reported and ~8% in constant currency from ~$5.15 billion in fiscal 2025, ~$4.69 billion in fiscal 2024 and ~$4.22 billion in fiscal 2023. The September 2026 quarter, the first of fiscal 2027, produced ~$1.41 billion, up ~5.9% year on year and slightly above the ~$1.39 billion consensus, after the Astral sales suspension and the MatrixCare divestiture.. The bear case rests on philips is the single largest competitive variable. Analysts covering it are spread from $210.00 to $320.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Should I sell RMD?

+

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Philips is the single largest competitive variable. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $210.00, -10.9% from the $235.63 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.

What is the bull case for RMD?

+

Resupply, not new device placements, carries the growth. Masks and other consumables grew 10% in the Americas and 12% internationally on a constant currency basis in the June 2026 quarter, faster than device revenue in both regions. The most optimistic analyst target on RMD is $320.00, +35.8% from the $235.63 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for RMD?

+

Philips is the single largest competitive variable. Its Respironics business exited most of the US new device market after the 2021 foam recall and the subsequent consent decree, handing ResMed several points of share it did not have to compete for. Any credible return of Philips capacity to the US sleep market would meet a ResMed that has been pricing and allocating capital against a diminished rival for five years, and mask share, where switching costs are lowest, would be the first place to show it. The GLP-1 question is genuinely open. ResMed's 2.5 million patient study is observational and self published, and it measures behaviour in the early years of drug adoption rather than the steady state after sustained weight loss; a cohort that loses enough weight to fall below the diagnostic threshold would leave the resupply base entirely. Quality systems are the second live risk. A Class 1 designation on 168,069 Astral units invites FDA scrutiny that can extend past the specific defect into inspection findings, warning letters or a consent decree, and Philips is the cautionary case for how far that can go. Reimbursement adds pressure from the other side: most US revenue passes through home medical equipment suppliers paid by Medicare and commercial plans, so competitive bidding rounds and prior authorisation tightening compress the distributor before they reach ResMed. Manufacturing is concentrated in Singapore, Sydney and Tijuana, which leaves the gross margin exposed to tariffs and freight. Roughly a third of revenue is non-US, so a stronger dollar reduces reported growth. Finally, short interest near 10.9% in August and a 52 week range of $180.27 to $277.67, with the stock ~2.3% lower over a year even as trailing GAAP earnings grew to ~$1.59 billion and quarterly earnings rose ~23% year on year, mean sentiment, not fundamentals, has been setting the price. Revenue growth of ~5.9% in the September quarter, down from 9% in June, is the number the GLP-1 bears will point to until the Astral and MatrixCare effects lap. The most pessimistic published target is $210.00, -10.9% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.

What does ResMed do?

+

ResMed sells the devices, masks and cloud software used to treat sleep apnea and respiratory conditions outside the hospital.

What would have to change for RMD to stop being worth holding?

+

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Resupply, not new device placements, carries the growth) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (philips is the single largest competitive variable) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does ResMed do?

+

ResMed makes the equipment used to treat sleep apnea and chronic respiratory disease at home, and the software that supports the businesses distributing it. The core products are CPAP and bilevel flow generators (the AirSense and AirCurve families), the masks and cushions patients wear with them, and the Astral and Stellar life support ventilators. A third business, Residential Care Software, sells back office systems to home medical equipment dealers and out of hospital care providers. In fiscal 2026, the year ended June 30, 2026, devices generated ~$2.89 billion, masks and other consumables ~$2.09 billion and software ~$676 million of $5.65 billion in total revenue. Roughly 35 million devices are cloud connected and ~37 million patients are registered in the AirView monitoring platform.

Why did ResMed stock drop?

+

Shares fell about 6% after hours on the fiscal fourth quarter release of August 6, 2026, and as of November 20, 2026 they are ~2.3% lower than a year earlier at $238.24, after a rebound off the summer low near $180.27 and a ~5.8% slip over the past month. Two things drove the August drop. ResMed guided to roughly $75 million of lost fiscal 2027 revenue from a field safety action on its Astral ventilators, having taken a $42 million provision in the quarter and suspended new Astral sales. Quarterly revenue of ~$1.46 billion also came in fractionally below the ~$1.47 billion consensus, even though non-GAAP EPS of $2.95 beat the ~$2.89 expected. Underneath both sits a longer running argument about whether GLP-1 weight loss drugs shrink the sleep apnea patient pool, which has kept short interest near 10.9% of shares. The September quarter, a $0.24 EPS beat on ~5.9% revenue growth, did not change that debate.

Are GLP-1 drugs like Zepbound a threat to ResMed?

+

The bear argument holds that drugs treating obesity remove the underlying cause of obstructive sleep apnea, particularly since Eli Lilly's Zepbound gained an OSA indication. ResMed's counter is empirical. It studied 2.5 million patients and found that those prescribed a GLP-1 were 1,070 basis points more likely to begin PAP therapy than a matched cohort, with higher mask resupply rates at both one and three years after setup. The proposed mechanism is engagement: someone treating their weight is more likely to pursue a sleep diagnosis. The study is observational and covers the early adoption period rather than a steady state, so it does not settle the question. The market has not accepted it either, which is what the elevated short interest and compressed multiple reflect.

Walnut is informational, not investment advice, and gives no verdict on RMD. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026. Verify current figures with your broker before acting on them.

The case for and against similar stocks